Large-scale processing of recombinant retroviruses for gene therapy

Biotechnology Progress

Volumn 15, Issue 1, 1999, Pages 1-11

  Andreadis, Stylianos T ^a   Roth, Charles M ^a   Le Doux, Joseph M ^a   Morgan, Jeffrey R ^a   Yarmush, Martin L ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENE THERAPY; GENE TRANSFER; RECOMBINANT DNA TECHNOLOGY; RETROVIRUS;

CELL LINE; DNA, RECOMBINANT; GENE THERAPY; HUMANS; RETROVIRIDAE;

EID: 0032982642     PISSN: 87567938     EISSN: None     Source Type: Journal    
DOI: 10.1021/bp980106m     Document Type: Review

References (80)

1. Aboud, M.; Wolfson, M.; Hassan, Y.; Huleihel, M. Rapid purification of extracellular and intracellular Moloney murine leukemia virus. Arch. Virol. 1982, 71, 185-195.
2. Andersen, W. F. Human gene therapy. Science 1992, 256, 808-813.
3. Andreadis, S.; Brott, D. A.; Fuller, A. O.; Palsson, B. O. Moloney murine leukemia virus-derived retroviral vectors decay intracellularly with a half-life in the range of 5.5 to 7.5 hours. J. Virol. 1997, 71, 7541-7548.
4. Andreadis, S.; Palsson, B. O. Kinetics of Retrovirus Mediated Gene Transfer: The Importance of the Intracellular Half-life of Retroviruses. J. Theor. Biol. 1996, 182, 1-20.
5. Bieganski, R. M.; Fowler, A.; Morgan, J. R.; Toner, M. Stabilization of active recombinant retroviruses in amorphous dry state with trehalose. Biotechnol. Prog. 1998, 14, 615-620.
6. Bobo, R. H.; Laske, D. W.; Akbasak, A.; Morrison, P. F.; Dedrick, R. L.; Oldfield, E. H. Convection-enhanced delivery of macromolecules into the brain. Proc. Natl. Acad. Sci. U.S.A 1994, 91, 2076-2080.
7. Braas, G.; Searle, P. F.; Slater, N. K. H.; Lyddiatt, A. Strategies for the isolation and purification of retroviral vectors for gene therapy. Bioseparation 1996, 6, 211-228.
8. Burns, J. C.; Friedmann, T.; Driever, W.; Burrascano, M.; Yee, J. K. Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: Concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc. Natl. Acad. Sci U.S.A. 1993, 90, 8033-8037.
9. CDC Update: trends in AIDS incidence - United States, 1996. Morbidity Mortality Weekly Rep. 1997, 46, 861-867.
10. Chesebro, B.; Wehrly, K. Different murine cell lines manifest unique patterns of interference to superinfection by murine leukemia viruses. Virology 1985, 141, 119-129.
11. Chuck, A. C.; Clarke, M. F.; Palsson, B. O. Retroviral infection is limited by brownian motion. Hum. Gene Ther. 1996, 7, 1527-1534.
12. Chuck, A. S.; Palsson, B. O. Consistent and high rates of gene transfer can be obtained using flow-through transduction over a wide range of retroviral titers. Hum. Gene Ther. 1996, 7, 743-750.
13. Chuck, A. S.; Palsson, B. O. Membrane adsorption characteristics determine the kinetics of flow-through transductions. Biotechnol. Bioeng. 1996, 51, 260-270.
14. Cosset, F.-L.; Yasuhiro, T.; Battini, J.-L.; Weiss, R. A.; Collins, M. K. L. High-titer packaging cells producing recombinant retroviruses resistant to human serum. J. Virol. 1995, 69, 7430-7436.
15. Cote, J.; Garnier, A.; Massie, B.; Kamen, A. Serum-free production of recombinant proteins and adenoviral vectors by 293SF-3F6 cells. Biotechnol. Bioeng. 1998, 59, 567-575.
16. Crystal, R. G. Transfer of genes to humans: early lessons and obstacles to success. Science 1995, 270, 404-410.
17. Davis, J. L.; Witt, R. M.; Gross, P. R.; Hokanson, C. A.; Jungles, S.; Cohen, L. K.; Danos, O.; Spratt, S. K. Retroviral particles produced from a stable human-derived packaging cell line transduce target cells with very high efficiencies Hum. Gene Ther. 1997, 8, 1459-1467.
18. Dranoff, G.; Soiffer, R.; Lynch, T.; Mihm, M.; Jung, K.; Kolesar, K.; Liebster, L.; Lam, P.; Duda, R.; Mentzer, S.; Singer, S.; Tanabe, K.; Johnson, R.; Sober, A.; Bhan, A.; Clift, S.; Cohen, L.; Parry, G.; Rokovich, J.; Richards, L.; Drayer, J.; Berns, A.; Mulligan, R. C. A phase I study of vaccination with autologous, irradiated melanoma cells engineered to secrete human granulocyte-macrophage colony stimulating factor. Hum. Gene Ther. 1997, 7, 111-123.
19. Dunbar, C.; Kohn, D.; Karlsson, S. Retroviral mediated transfer of the cDNA for human glucocerebrosidase into hematopoietic stem cells of patients with Gaucher disease: A phase I study. Hum. Gene Ther. 1996, 7, 231-253.
20. Evans, C. H.; Robbins, P. D.; Ghivizzani, S. C.; Herndon, J. H.; Kang, R. Clinical trial to assess the safety, feasibility, and efficacy of transferring a potentially antiarthritic cytokine gene to human joints with rheumatoid arthritis. Hum. Gene Ther. 1996, 7, 1261-1280.
21. Fields, B. N.; Knipe, D. M. Virology; Raven Press: New York, 1985.
22. Finer, M. H.; Dull, T. J.; Qin, L.; Farson, D.; Roberts, M. R. kat: a high-efficiency retroviral transduction system for primary human T lymphocytes. Blood 1994, 83, 43-50.
23. Forestell, S. P.; Bohnlein, E.; Rigg, R. J. Retroviral end-point titer is not predictive of gene transfer efficiency: implications for vector production. Gene Ther. 1995, 2, 723-730.
24. Frankel-Conrat, H.; Kimball, P. C. Virology; Pretice-Hall, Englewood Cliffs, NJ, 1982.
25. Garnier, A.; Cote, J.; Nadeau, I.; Kamen, A.; Massie, B. Scale-up of the adenovirus expression system for the production of recombinant protein in human 293S cells. Cytotechnology 1994, 15, 145-155.
26. Graham, F. L. Growth of 293 cells in suspension culture J. Gen. Virol. 1987, 68, 937-940.
27. Grampp, G. E.; Applegate, M. A.; Stephanopoulos, G.; Kurkela, R.; Fraune, E.; Vihko, P. Cyclic operation of ceramic-matrix animal cell bioreactors for controlled secretion of an endocrine hormone. A comparison of single-pass and recycle modes of operation. Biotechnol. Prog. 1996, 12, 837-846.
28. Hammar, L. Concentration of biomaterials: virus concentration and viral protein isolation. Methods Enzymol. 1994, 228, 640-658.
29. Hammar, L.; Gilljam, G. Extraction of HIV-1 in aqueous two-phase systems to obtain a high yield of gp120. AIDS Res. Hum. Retroviruses 1990, 6, 1379-1388.
30. Hodgson, C. P. The vector void in gene therapy. Bio/Technology 1995, 13, 222-225.
31. Hunter, E. Viral entry and receptors. In Retroviruses; Coffin, J. M., Hughes, S. H., Varmus, H. E., Eds.; Cold Spring Harbor Laboratory Press: New York, 1997; pp 71-119.
32. Julias, J. G.; Hash, D.; Pathak, V. K. E-vectors: development of novel self-inactivating and self-activating retroviral vectors for safer gene therapy. J. Virol. 1995, 69, 6839-6846.
33. Kafri, T.; Blomer, U.; Peterson, D. A.; Gage, F. H.; Verma, I. M. Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors. Nat. Genet. 1997, 17, 314-317.
34. Kasahara, N.; Dozy, A. M.; Kan, Y. W. Tissue-specific targeting of retroviral vectors through ligand-receptor interactions. Science 1994, 266, 1373-1376.
35. Kotani, H.; Newton, P. B. I.; Zhang, S.; Chiang, Y. L.; Otto, E.; Weaver, L.; Blaese, R. M.; Anderson, W. F.; McGarrity, G. J. Improved methods of retroviral vector transduction and production for gene therapy. Hum. Gene Ther. 1994, 5, 19-28.
36. Le Doux, J. M.; Davis, H. E.; Morgan, J. R.; Yarmush, M. L. Kinetics of retrovirus production and decay. Biotechnol. Bioeng. 1998, in press.
37. Le Doux, J. M.; Morgan, J. R.; Yarmush, M. L. Gene therapy. In Biomedical Engineering Handbook; Bronzino, G. J., Ed.; CRC Press: New York, 1995; pp 1518-1535.
38. Le Doux, J. M.; Morgan, J. R.; Yarmush, M. L. Proteoglycans secreted by packaging cell lines inhibit retrovirus infection. J. Virol. 1996, 70, 6468-6473.
39. Le Doux, J. M.; Morgan, J. R.; Yarmush, M. L. Removal of proteoglycans increases efficiency of retroviral gene transfer. Biotechnol. Bioeng. 1998, 58, 23-34.
40. Levy, J. A.; Friedsteel, A. H. Freeze-drying is an effective method for preserving infectious type C retroviruses. J. Virol. Methods 1982, 5, 165-171.
41. Luria, S. E. General Virology, 3rd ed.; Wiley: New York, 1978.
42. Makino, M.; Ishikawa, G.; Yamaguchi, K.; Okada, Y.; Watanabe, K.; Sasaki-Iwaki, Y.; Manabe, S.; Honda, M.; Komuro, K. Concentration of live retrovirus with a regenerated cellulose hollow fiber, BMM. Arch. Virol. 1994, 139, 87-96.
43. McGrath, M.; Witte, O.; Pincus, T.; Weissman, I. L. Retrovirus purification: method that conserves envelope glycoprotein and maximizes infectivity. J. Virol. 1978, 25, 923-927.
44. Miller, A. D. Cell-surface receptors for retroviruses and implications for gene transfer. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 11407-11413.
45. Miller, A. D. Human gene therapy comes of age. Nature 1992, 357, 455-460.
46. Miller, A. D.; Garcia, J. V.; von Suhr, N.; Lynch, C. M.; Wilson, C.; Eiden, M. V. Construction and properties of retrovirus packaging cells based on gibbon ape leukemia virus. J. Virol. 1991, 65, 2220-2224.
47. Miyoshi, H.; Takahashi, M.; Gage, F. H.; Verma, I. M. Stable and efficient gene transfer into the retina using an HIV-based lentiviral vector. Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 10319-23.
48. Morgan, J. R.; Tompkins, R. G.; Yarmush, M. L. Advances in recombinant retroviruses for gene delivery. Adv. Drug Delivery Rev. 1993, 12, 143-158.
49. Morgan, J. R.; Yarmush, M. L. Gene therapy in tissue engineering. In Frontiers in Tissue Engineering; Patrick, C. W., Jr., Mikos, A., McIntire, L. V., Eds.; Pergamon: New York, 1998; pp 278-310.
50. Morgan, R. A.; Walker, R. Gene therapy for AIDS using retroviral mediated gene transfer to deliver HIV-1 antisense TAR and transdominant Rev protein genes to syngeneic lymphocytes in HIV-1 infected identical twins. Hum. Gene Ther. 1996, 7, 1281-1306.
51. Morling, F. G.; Russell, S. J. Enhanced transduction efficiency of retroviral vectors coprecipitated with calcium phosphate. Gene Ther. 1995, 2, 504-508.
52. Morrison, P. F.; Laske, D. W.; H., B.; Oldfield, E. H.; Dedrick, R. L. High-flow microinfusion: tissue penetration and pharmacodynamics. Am. J. Physiol. 1994, 35, R292-R305.
53. Mulligan, R. C. The basic science of gene therapy. Science 1993, 260, 926-932.
54. Nadeau, I.; Garnier, A.; Cote, J.; Massie, B.; Chavarie, C.; Kamen, A. Improvement of recombinant protein production with the human adenovirus/293S expression system using fed-batch strategies. Biotechnol. Bioeng. 1996, 51, 613-623.
55. Naldini, L.; Blomer, U.; Gage, F. H.; Trono, D.; Verma, I. M. Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 11382-11388.
56. Naldini, L.; Blomer, U.; Gallay, P.; Ory, D.; Mulligan, R.; Gage, F. H.; Verma, I. M.; Trono, D. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996, 272, 263-267.
57. Naviaux, R. K.; Costanzi, E.; Haas, M.; Verma, I. M. The pCL vector system: rapid production of helper-free, high titer, recombinant retroviruses. J. Virol. 1996, 70, 5701-5705.
58. NIH National Gene Vector Laboratories. NIH Guide 1994, 23.
59. O'Neil, P. F.; Balcovic, E. S. Virus harvesting and affinity-based chromatography. Bio/Technology 1993, 11, 173-178.
60. Olsen, J. C.; Sechelski, J. Use of sodium butyrate to enhance production of retroviral vectors expressing CFTR cDNA. Hum. Gene Ther. 1995, 6, 1195-1202.
61. Orkin, S. H.; Motulsky, A. G. Report and recommendations of the panel to assess the NIH investment in research on gene therapy, NIH, 1995.
62. Palsson, B. O.; Andreadis, S. The physico-chemical factors that govern retrovirus-mediated gene transfer. Exp. Hematol. 1997, 25, 94-102.
63. Paul, R. W.; Morris, D.; Hess, B. W.; Dunn, J.; Overell, R. W. Increased viral titer through concentration of viral harvests from retroviral packaging cell lines. Hum. Gene Ther. 1993, 4, 609-615.
64. Perales J. C.; Grossman, G. A.; Molas, M.; Liu, G.; Ferkol, T.; Harpst, J.; Oda, H.; Hanson, R. W. Biochemical and functional characterization of DNA complexes capable of targeting genes to hepatocytes via the asialoglycoprotein receptor. J. Biol. Chem. 1997, 14, 7398-7407.
65. Peshwa, M. V.; Kyung, Y. S.; McClure, D. B.; Hu, W. S. Cultivation of mammalian cells as aggregates in bioreactors: effect of calcium concentration on spatial distribution of viability. Biotechnol. Bioeng. 1993, 41, 179-187.
66. Prussak, C. E. Method for the purification or removal of retroviruses using sulfated cellulose. U.S. Patent 5,447,859, 1995.
67. Reiser, J.; Harmison, G.; Kluepfel-Stahl, S.; Brady, R. O.; Karlsson, S.; Schubert, M. Transduction of nondividing cells using pseudotyped defective high-titer HIV type 1 particles. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 15266-15271.
68. Rigg, R. J.; Chen, J.; Dando, J. S.; Forestell, S. P.; Plavec, I.; Bohnlein, E. A novel human amphotropic packaging cell line: high titer, complement resistance, and improved safety. Virology 1996, 218, 290-295.
69. Rimai, L.; Salmeen, I.; Hart, D.; Liebes, L.; Rich, M. A.; McConnick, J. J. Electrophoretic mobilities of RNA tumor viruses. Studies by Doppler-shifted light scattering spectroscopy. Biochemistry 1975, 14, 4621-4627.
70. Roemer, K.; Friedmann, T. Concepts and strategies for human gene therapy. Eur. J. Biochem. 1992, 208, 221-225.
71. Roth, J. A. Modification of tumor suppressor gene expression in nonsmall cell lung cancer (NSCLC) with a retroviral vector expressing wildtype (normal) p53. Hum. Gene Ther. 1998, 7, 861-874.
72. Saha, K.; Lin, Y.-C.; Wong, P. K. Y. A simple method for obtaining highly viable virus from culture supernatant. J. Virol. Methods 1994, 46, 349-352.
73. Salmeen, I.; Rimai, L.; Liebes, L.; Rich, M. A.; McCormick, J. J. Hydrodynamic diameters of RNA tumor viruses. Studies by laser beat frequency light scattering spectroscopy of avian myeloblastosis and Raucher murine leukemia viruses. Biochemistry 1975, 14, 134-141.
74. Sanes, J. R.; Rubenstein, J. L. R.; Nicolas, J. F. Use of a recombinant retrovirus to study post implantation cell lineage in mouse embryos. EMBO J. 1986, 5, 3133-3142.
75. Shen, B. Q.; Clarke, M. F.; Palsson, B. O. Kinetics of retroviral production from the amphotropic ψCRIP murine producer cell line. Cytotechnology 1996, 22, 185-195.
76. Torrent, C.; Bordet, T.; Darlix, J. L. Analytical study of rat retrotransposon VL30 RNA dimerization in vitro and packaging in murine leukemia virus. J. Mol. Biol. 1994, 240, 434-444.
77. Wilson, C.; Reitz, M. S.; Okayama, H.; Eiden, M. V. Formation of infectious hybrid virions with gibbon ape leukemia virus and human T-cell leukemia virus retroviral envelope glycoproteins and the gag and pol proteins of Moloney murine leukemia virus. J. Virol. 1989, 63, 2374-2378.
78. Wilson, C. A.; Ng, T. H.; Miller, A. E. Evaluation of recommendations for replication-competent retrovirus testing associated with use of retroviral vectors. Hum. Gene Ther 1997, 8, 869-874.
79. Wingo, P. A.; Ries, L. A.; Rosenberg, H. M.; Miller, D. S.; Edwards, B. K. Cancer incidence and mortality, 1973-1995: A report card for the U.S. Cancer 1998, 82, 1197-1207.
80. Yu, S. F.; von Ruden, T.; Kantoff, P. W.; Garber, C.; Seiberg, M.; Ruther, U.; Anderson, W. F.; Wagner, E. F.; Gilboa, E. Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells. Proc. Natl. Acad Sci. U.S.A. 1986, 83, 3194-3198.